Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes

Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss

doi:10.1128/jvi.78.5.2627-2631.2004

Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes

J Virol. 2004 Mar;78(5):2627-31. doi: 10.1128/jvi.78.5.2627-2631.2004.

Authors

Eve de Rosny¹, Russell Vassell, Shibo Jiang, Renate Kunert, Carol D Weiss

Affiliation

¹ Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892-4555, USA.

Abstract

We investigated how the broadly neutralizing monoclonal antibody 2F5 affects the human immunodeficiency virus type 1 envelope glycoprotein as it undergoes receptor-induced conformational changes and show that 2F5 binds both native and fusion-intermediate conformations, suggesting inhibition of a late step in virus entry. We also demonstrate conformational changes in the C heptad of gp41.

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antibodies, Monoclonal / immunology*
Antibodies, Monoclonal / pharmacology
Antibody Specificity*
CD4 Antigens / metabolism
CD4 Antigens / pharmacology
Epitopes / chemistry
Epitopes / immunology
HIV Envelope Protein gp41 / chemistry*
HIV Envelope Protein gp41 / immunology*
HIV-1 / chemistry
HIV-1 / immunology
HIV-1 / physiology
Membrane Fusion*
Neutralization Tests
Protein Conformation
Solubility

Substances

Antibodies, Monoclonal
CD4 Antigens
Epitopes
HIV Envelope Protein gp41